SOLICITATION NOTICE
Q -- NCI Vaccine Branch Retrovirus Assay, Reagent, and Viral Stock Preparation Support
- Notice Date
- 7/11/2023 12:44:16 PM
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- NIH NCI Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NCI-RFI-SAB-0001-82
- Response Due
- 7/21/2023 7:00:00 AM
- Archive Date
- 07/21/2023
- Point of Contact
- John Russell, Contracting Officer, Reyes Rodriguez, Contracting Officer
- E-Mail Address
-
John.Russell3@nih.gov, reyes.rodriguez@nih.gov
(John.Russell3@nih.gov, reyes.rodriguez@nih.gov)
- Description
- This is a Request for Information (RFI) and is for informational and planning purposes only. This notice shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this RFI is to identify qualified business concerns, especially small businesses, that are interested in and capable of performing the work described herein. As well, as solicit information from industry pertaining to the nature and capabilities of vendors to perform the specified services. The NCI does not intend to award a contract based on responses received nor otherwise pay for the preparation of any information submitted. Responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a small business set aside is possible. The requirement�s suggested North American Industry Classification System (NAICS) code is 541380 (Testing Laboratories and Services) with a size standard of $19.0 Million. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise because of a response to this RFI or the NCI�s use of such information furnished in response to this notice.� RESPONSE INSTRUCTIONS: Responses to this notice shall be submitted via email to Contract Specialist, John Russell , at John.Russell3@nih.govno later than 10:00 A.M. EST on Thursday, July 27, 2023 (07/27/23). All information furnished must be in writing and must contain enough detail to allow the NCI to determine the respondents� ability to meet the requirements described herein. A response should not exceed 10 single-sided pages including all attachments, charts, etc. (single space, 12-point font minimum) that clearly responds to the below questions. All proprietary information should be clearly marked as such. Please reference the notice number HHS?NIH?NCI?RFI?SAB?0001?82 on all correspondence.� Requested Information: Please provide the following information in your company�s response:� 1.�� �Company Name� 2.�� �Point of Contact (POC) (including telephone and email address) 3.�� �Company�s System for Award Management Unique Entity Identifier (UEI) 4.�� �Socio-economic status (8(a), SDVOSB, VOSB, Woman-Owned, Other� etc.). 5.�� �Information on any currently held government contracts to include: a.�� �Contract Number b.�� �Type of Contract c.�� �Contracting Agency (GSA, SEWP, etc.) d.�� �If you hold a current GSA schedule contract, specify which SINs are best suited for providing the services/items specified in the SOW. 6.�� �Are these services commercial in nature (e.g., Commonly sold to the Government and non-government entities under general terms and conditions)?� 7.�� �Does your company have any available pricing information pertaining to the various assay, or reagent/viral stock preparation services? 8.�� �Does your company have BSL Level 2 Facilities, or the ability to utilize a BSL Level 2 Facility? 9.�� �Would storage facilities for temporary housing of samples of this scale normally be provided for commercial services? 10.�� �How would shipment, receiving, and tracking of samples be accomplished? 11.�� �Has your company provided these services for the Government in the past? If so, please provide the contract number, agency, and agency point of contact.� Please see the attachments for more information: -�� �Draft IDIQ Statement of Work titled �Animal Models and Retroviral Vaccines section (AMRVS) Retrovirus Assay, Reagent, and Viral Stock Preparation Support� � �� This RFI notice does not obligate the Government to award a contract or otherwise pay for�the information provided in response. The Government reserves the right to use the information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is�complete and sufficiently detailed to allow the Government to determine the organization�s capability. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. Information provided by small businesses will be given precedence over other than small business respondents to determine whether the requirement can be conducted as a small business set aside. After a review of the responses� received, a synopsis and solicitation may be published. However, responses to this notice will not be considered an adequate response to a solicitation(s).
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/da110d7d9308469dbaee895b83178939/view)
- Place of Performance
- Address: Bethesda, MD, USA
- Country: USA
- Country: USA
- Record
- SN06743562-F 20230713/230711230049 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |